Ann: Quarterly Activities/Appendix 5B Cash Flow Report, page-16

You can see from some of my posts that I have been critical of the old board (as I am whenever I have seen directors sell in the marrow stage).

Not withstanding their professional backgrounds and, as I have pointed out, the greed at play in how they have treated the paper they have been issued.
In that, total disregard for how shareholders perceive thier sales(force sales) by directors might be swaying the stock price.

But this is the game at this end of town, and so it's the gamble you take when you invest in a marrow.

I wonder how Mr Rinaldi feels about this, and I'd be interested to ask him how he sees this play out. (more on this later)


https://www.marketindex.com.au/asx/bnl?src=search-all

Then could it be that the last raise of 7m was a throw of the dice, driven by the gambling nature of the management?


The questions are now (for new money to flow in)

That last point is moot up to this point, as we know they haven't given an iota about shareholders and dilution at this point in time I haven't read anywhere that they have felt any remorse on that last bad decision ..

Let's explore that a bit more.



I will add a table of Wells to the research post as I get time, and I'll put them all together.

This has been one of my peeves. There is a long list of "we are getting approvals," and sure, pre-2022, it bumped the share price, but now it's more of a liability than anything else. (Farm-outs incoming, maybe?)

I need to do a bit more data matching as yet as just trawling through the years of releases..


Keep in mind the new board members.. (further down a bit more on this)

It's still a dam interesting story (yes, I took that loss a while ago and still holding a few as a sucker for punishment).

So what are we looking for now?

then back to this as State 16 has flowed..

I will wrap it up, as it's never a short one when you dig deep into a story like this.